In a CotW a few weeks ago we postulated that based on biomarker discovery work Celgene is poised to dominate personalized medicine.  However, this week’s chart suggests that if Celgene’s rise in personalized medicine is to happen it could be a long ways off.  Other big pharma are getting biomarkers to market faster.

 

innovative_company_comparison_point.png

Share this Image On Your Site

<p><strong>Please include attribution to amplion.com with this graphic.</strong><br /><br /><a href=”><img src=’https://amplion.com/wp-content/uploads/2016/04/innovative_company_comparison_point.png’ alt=’Innovative Pharma Comparison’ width=’540px’ border=’0′ /></a></p>

Do you need similar analysis?

[plsc_button url=”https://amplion.wpengine.com/consulting?hsCtaTracking=0ecabe42-acda-48e9-b2bd-1a020165bdb3%7Cb6240f02-690a-44c9-8446-a7209594c70a” target=”_blank” color=”green” style=”flat” radius=”square” size=”lg”]TALK TO A CONSULTANT[/plsc_button]

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access